Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development
Alivio Therapeutics Inc
GlycoMira Therapeutics Inc
Grunenthal GmbH
Harrow Health Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Pierre Fabre Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles
(heparin sodium + lidocaine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAY-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obotulinumtoxi - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women’s Health Conference
Sep 12, 2018: U.S. Department of Defense awards $3.3 million grant to Alivio Therapeutics
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
May 18, 2015: Cadian Jourl of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combition Formulation for the Relief of Interstitial Cystitis Symptoms
Jun 30, 2011: Urigen Provides Development Update For URG101
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
Apr 23, 2010: Urigen Files Request For FDA Meeting
Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
Apr 25, 2008: Urigen Announces US Patent Office Notice Of Allowance Of Claims For URG101
Apr 07, 2008: Urigen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Alysis Results
Dec 05, 2007: Urigen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Alivio Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by GlycoMira Therapeutics Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Grunenthal GmbH, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Harrow Health Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Mirae Cell Bio Co Ltd, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2019
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products, H2 2019